Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus

  • Wadelius, Mia|||0000-0002-6368-2622
  • Eriksson, Niclas
  • Kreutz, Reinhold
  • Bondon-Guitton, Emmanuelle
  • Ibáñez, Luisa|||0000-0002-1175-0574
  • Carvajal, Alfonso
  • Lucena, M. Isabel|||0000-0001-9586-4896
  • Sancho Ponce, Esther
  • Molokhia, Mariam
  • Martin-Martinez, J.|||0000-0001-5938-5898
  • Axelsson, Tomas
  • Kohnke, Hugo
  • Yue, Qun-Ying
  • Magnusson, Patrik K. E.|||0000-0002-7315-7899
  • Bengtsson, Mats
  • Hallberg, Pär
Agranulocytosis is a serious, although rare, adverse reaction to sulfasalazine, which is used to treat inflammatory joint and bowel disease. We performed a genome-wide association study comprising 9,380,034 polymorphisms and 180 HLA alleles in 36 cases of sulfasalazine-induced agranulocytosis and 5,170 population controls. Sulfasalazine-induced agranulocytosis was significantly associated with the HLA region on chromosome 6. The top hit (rs9266634) was located close to HLA-B, odds ratio (OR) 5.36 (95% confidence interval (CI) (2.97, 9.69) P = 2.55 × 10 -8). We HLA-sequenced a second cohort consisting of 40 cases and 142 treated controls, and confirmed significant associations with HLA-B*08:01, OR = 2.25 (95% CI (1.02, 4.97) P = 0.0439), in particular the HLA-B*08:01 haplotype HLA-DQB1*02:01-DRB1*03:01-B*08:01-C*07:01, OR = 3.79 (95% CI (1.63, 8.80) P = 0.0019), and with HLA-A*31:01, OR = 4.81 (95% CI (1.52, 15.26) P = 0.0077). The number needed to test for HLA-B*08:01 and HLA-A*31:01 to avoid one case was estimated to be 1,500. We suggest that intensified monitoring or alternative treatment should be considered for known carriers of HLA-B*08:01 or HLA-A*31:01.